• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 vaccines: fast track versus efficacy.

作者信息

Alkandari Dana, Herbert Jenny A, Alkhalaf Moustafa A, Yates Carol, Panagiotou Stavros

机构信息

Division of Medical Education, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PT, UK.

出版信息

Lancet Microbe. 2021 Mar;2(3):e89-e90. doi: 10.1016/S2666-5247(21)00034-3. Epub 2021 Feb 9.

DOI:10.1016/S2666-5247(21)00034-3
PMID:33659918
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7906641/
Abstract
摘要

相似文献

1
SARS-CoV-2 vaccines: fast track versus efficacy.严重急性呼吸综合征冠状病毒2型疫苗：快速审批与疗效
Lancet Microbe. 2021 Mar;2(3):e89-e90. doi: 10.1016/S2666-5247(21)00034-3. Epub 2021 Feb 9.
2
COVID-19 vaccines and decreased transmission of SARS-CoV-2.COVID-19 疫苗与 SARS-CoV-2 传播减少。
Inflammopharmacology. 2021 Oct;29(5):1357-1360. doi: 10.1007/s10787-021-00847-2. Epub 2021 Jul 19.
3
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.临床试验中 SARS-CoV-2 疫苗的免疫原性和安全性。
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.
4
Special focus 'SARS-CoV-2 / COVID-19: advances in developing vaccines and immunotherapeutics'.特别关注“SARS-CoV-2 / COVID-19：疫苗和免疫疗法研发进展”
Hum Vaccin Immunother. 2020 Dec 1;16(12):2888-2890. doi: 10.1080/21645515.2020.1847952.
5
Talk of the town in 2021: Covid-19 vaccines likely take centre stage.2021年的热门话题：新冠疫苗很可能成为焦点。
Scand J Immunol. 2021 Jan;93(1):e13014. doi: 10.1111/sji.13014.
6
Safety of mRNA-Based Vaccines for SARS CoV-2.mRNA 疫苗在 SARS-CoV-2 中的安全性。
Chem Res Toxicol. 2021 Aug 16;34(8):1823-1825. doi: 10.1021/acs.chemrestox.1c00129. Epub 2021 May 19.
7
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.在初始候选疫苗获得紧急使用授权或批准上市后评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗
JAMA. 2021 Jan 19;325(3):221-222. doi: 10.1001/jama.2020.25127.
8
Migraine treatment and COVID-19 vaccines: No cause for concern.偏头痛治疗与新冠疫苗：无需担忧。
Headache. 2021 Mar;61(3):409-411. doi: 10.1111/head.14086.
9
Covid-19 vaccines for teenagers: conversations and consent.青少年新冠疫苗接种：沟通与同意
BMJ. 2021 Sep 22;374:n2312. doi: 10.1136/bmj.n2312.
10
COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic.新冠疫苗：迈向终结大流行全球影响开端的一步。
Anaesthesia. 2021 Apr;76(4):435-443. doi: 10.1111/anae.15365. Epub 2020 Dec 14.

引用本文的文献

1
Political Affiliation, Policy Measures, and Intention to Receive COVID-19 and Influenza Vaccines.政治归属、政策措施以及接种新冠疫苗和流感疫苗的意愿
Int J Environ Res Public Health. 2024 Nov 30;21(12):1608. doi: 10.3390/ijerph21121608.
2
The outcome and related risk factors of unvaccinated patients with end-stage kidney disease during the Omicron pandemic: a multicentre retrospective study.奥密克戎疫情期间未接种疫苗的终末期肾病患者的结局和相关风险因素：一项多中心回顾性研究。
BMJ Open. 2024 May 15;14(5):e084649. doi: 10.1136/bmjopen-2024-084649.
3
Effectiveness of vaccination in reducing hospitalization and mortality rates in dialysis patients with Omicron infection in China: A single-center study.中国奥密克戎感染透析患者疫苗接种降低住院和死亡率的效果：一项单中心研究。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2252257. doi: 10.1080/21645515.2023.2252257.
4
Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review.抗SARS-CoV-2疫苗在肝硬化患者中的疗效、安全性和免疫原性：一项叙述性综述。
Vaccines (Basel). 2023 Feb 16;11(2):452. doi: 10.3390/vaccines11020452.
5
Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.通过在明矾/纳洛酮佐剂中配制来提高灭活新冠病毒疫苗效力；强大的T细胞和抗受体结合域IgG反应
Iran J Basic Med Sci. 2022 May;25(5):554-561. doi: 10.22038/IJBMS.2022.63527.14015.
6
Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.评估刚果个体自然感染 SARS-CoV-2 和接种疫苗后的中和抗体反应。
BMC Infect Dis. 2022 Jul 13;22(1):610. doi: 10.1186/s12879-022-07593-y.
7
COVID-19 vaccine: A 2021 analysis of perceptions on vaccine safety and promise in a U.S. sample.COVID-19 疫苗：2021 年美国样本中对疫苗安全性和前景的认知分析。
PLoS One. 2022 May 19;17(5):e0268784. doi: 10.1371/journal.pone.0268784. eCollection 2022.
8
Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems.针对新型冠状病毒的肽基疫苗：肽抗原的发现与佐剂系统筛选
Pharmaceutics. 2022 Apr 13;14(4):856. doi: 10.3390/pharmaceutics14040856.
9
Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection.奥密克戎 SARS-CoV-2 变异株感染的突变模式、影响及潜在预防策略
Infect Drug Resist. 2022 Apr 15;15:1871-1887. doi: 10.2147/IDR.S360103. eCollection 2022.
10
Affordable IgY-based antiviral prophylaxis for resource-limited settings to address epidemic and pandemic risks.负担得起的 IgY 抗病毒预防措施，用于资源有限的环境，以应对疫情和大流行风险。
J Glob Health. 2022 Feb 26;12:05009. doi: 10.7189/jogh.12.05009. eCollection 2022.

本文引用的文献

1
Looking beyond COVID-19 vaccine phase 3 trials.展望 COVID-19 疫苗 III 期临床试验之外。
Nat Med. 2021 Feb;27(2):205-211. doi: 10.1038/s41591-021-01230-y. Epub 2021 Jan 19.
2
Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination.新冠疫情：挪威对体弱老年患者接种疫苗后出现的23例死亡病例展开调查。
BMJ. 2021 Jan 15;372:n149. doi: 10.1136/bmj.n149.
3
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
4
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
5
Combating vaccine hesitancy and other 21st century social determinants in the global fight against measles.在全球抗击麻疹的斗争中，应对疫苗犹豫和其他 21 世纪的社会决定因素。
Curr Opin Virol. 2020 Apr;41:1-7. doi: 10.1016/j.coviro.2020.01.001. Epub 2020 Feb 26.
6
Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases.治疗传染病药物的研发时间和审批成功率。
Clin Pharmacol Ther. 2020 Feb;107(2):324-332. doi: 10.1002/cpt.1627. Epub 2019 Oct 11.
7
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.利用反向疫苗学开发 B 型脑膜炎球菌疫苗。
Front Immunol. 2019 Apr 16;10:751. doi: 10.3389/fimmu.2019.00751. eCollection 2019.
8
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study.估算针对流行性传染病的疫苗开发成本：成本最小化研究。
Lancet Glob Health. 2018 Dec;6(12):e1386-e1396. doi: 10.1016/S2214-109X(18)30346-2. Epub 2018 Oct 18.
9
Rotarix: a rotavirus vaccine for the world.罗特威（Rotarix）：一款面向全球的轮状病毒疫苗。
Clin Infect Dis. 2009 Jan 15;48(2):222-8. doi: 10.1086/595702.